Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

TEM

Tempus AI Inc

Mar 10 • 04:00PM ET

50.90

-1.42 -2.71 %

Healthcare • Health Information Services • USA • NASD

Peers: ILMN EXAS GH TXG CRSP PACB NTLA EDIT CDNA TWST

| Held by: ARKK VTI VB ARKG VBK VXF BAI IBB IWP JTEK

Index	-	P/E	-	EPS (ttm)	-1.41	Insider Own	41.63%	Shs Outstand	173.24M	Perf Week	-0.97%
Market Cap	9.06B	Forward P/E	-	EPS next Y	-0.05	Insider Trans	-2.23%	Shs Float	103.85M	Perf Month	-7.30%
Enterprise Value	9.63B	PEG	-	EPS next Q	-0.19	Inst Own	52.41%	Short Float	21.89%	Perf Quarter	-33.60%
Income	-245.03M	P/S	7.12	EPS this Y	34.02%	Inst Trans	3.87%	Short Ratio	4.32	Perf Half Y	-36.55%
Sales	1.27B	P/B	18.47	EPS next Y	87.58%	ROA	-15.31%	Short Interest	22.73M	Perf YTD	-13.80%
Book/sh	2.76	P/C	11.99	EPS next 5Y	-	ROE	-89.48%	52W High	104.32 -51.21%	Perf Year	12.69%
Cash/sh	4.24	P/FCF	-	EPS past 3/5Y	10.57% 1.21%	ROIC	-13.57%	52W Low	36.22 40.53%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	58.29% 46.57%	Gross Margin	61.46%	Volatility	4.87% 5.98%	Perf 5Y	-
Dividend TTM	-	EV/Sales	7.57	EPS Y/Y TTM	70.36%	Oper. Margin	-19.16%	ATR (14)	3.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.00	Sales Y/Y TTM	83.41%	Profit Margin	-19.27%	RSI (14)	38.60	Recom	1.89
Dividend Gr. 3/5Y	- -	Current Ratio	3.13	EPS Q/Q	-278.33%	SMA20	-5.86%	Beta	5.23	Target Price	77.93
Payout	-	Debt/Eq	2.70	Sales Q/Q	82.98%	SMA50	-14.93%	Rel Volume	0.81	Prev Close	52.32
Employees	3800	LT Debt/Eq	2.67	Earnings	Feb 24 AMC	SMA200	-26.88%	Avg Volume	5.26M	Price	50.90
IPO	Jun 14, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-19.76% 1.21%	Trades		Volume	4,280,110	Change	-2.71%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-19-26	Initiated	Mizuho	Outperform	$100
Feb-17-26	Initiated	Robert W. Baird	Outperform	$59
Dec-02-25	Resumed	Morgan Stanley	Overweight	$85
Oct-21-25	Downgrade	TD Cowen	Buy → Hold	$88
Oct-20-25	Initiated	Canaccord Genuity	Buy	$110
Sep-02-25	Initiated	H.C. Wainwright	Buy	$90
Apr-21-25	Initiated	BTIG Research	Buy	$60
Feb-25-25	Downgrade	JP Morgan	Overweight → Neutral	$50 → $55
Feb-12-25	Downgrade	William Blair	Outperform → Mkt Perform
Feb-05-25	Resumed	TD Cowen	Buy	$58 → $74
Dec-13-24	Initiated	Wolfe Research	Outperform	$60
Dec-09-24	Initiated	Guggenheim	Buy	$74
Nov-11-24	Downgrade	Stifel	Buy → Hold	$45 → $65
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $60
Aug-12-24	Initiated	Piper Sandler	Neutral	$40
Jul-09-24	Initiated	William Blair	Outperform
Jul-09-24	Initiated	TD Cowen	Buy	$50
Jul-09-24	Initiated	Stifel	Buy	$45
Jul-09-24	Initiated	Needham	Buy	$47
Jul-09-24	Initiated	Morgan Stanley	Overweight	$44

Show Previous Ratings

Mar-10-26 01:33PM	Hims and Hers Expands Consumer-Focused Digital Health Platform (Zacks)
Mar-09-26 08:52AM	Should You Buy, Hold or Sell Tempus AI Stock Heading Into 2026? (Zacks)
Mar-07-26 07:11AM	Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine (Insider Monkey)
Mar-05-26 08:44AM	TEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth? (Zacks)
Mar-04-26 06:00PM	Is Tempus AI, Inc. (TEM) A Good Stock To Buy Now? (Insider Monkey)
02:33PM	Loading…
Mar-03-26 02:33PM	AI-Powered Tempus Inks New Multi-Year Merck Deal (Benzinga)
12:19PM	Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes (PR Newswire)
08:30AM	Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine (Business Wire)
Mar-01-26 08:00AM	Consumer Tech News (Feb 23-27): US-Taiwan Trade Tensions Escalates, Amazon Invests $12B In US & More (Benzinga)
Feb-26-26 10:48AM	TEM vs. ILMN: Which MedTech Stock Offers Greater Upside? (Zacks)
08:30AM	Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference (Business Wire)
Feb-25-26 09:20PM	Cathie Wood Is Buying The Tempus AI Dip, Ark Snaps Up Stock Worth $11 Million (Benzinga) -7.32%
09:44AM	Tempus AI Posts 83% Revenue Growth Yet Stumbles on Full Year Profitability Target (24/7 Wall St.)
08:30AM	Tempus AI, Inc. Q4 2025 Earnings Call Summary (Moby)
07:26AM	TEM Q4 Earnings Miss, Revenues Beat, Stock Down in After-Market (Zacks)
01:07AM	Loading…
01:07AM	Tempus AI Q4 Earnings Call Highlights (MarketBeat)
12:02AM	Tempus AI Inc (TEM) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
Feb-24-26 08:19PM	AMD, Zeta Global, MercadoLibre, Tempus AI And Workday: Why These 5 Stocks Are On Investors' Radars Today (Benzinga)
07:30PM	Tempus AI (TEM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
05:32PM	Tempus AI Stock Drops Despite Q4 Earnings Beat: Details (Benzinga)
04:01PM	Tempus Reports Fourth Quarter and Full Year 2025 Results (Business Wire)
Feb-23-26 10:33AM	Nvidia, Joby, CoreWeave, Lucid and More Stocks with Earnings This Week (Benzinga)
07:46AM	AppLovin Surges 11% While Tempus AI and Micron Also Outpace Most AI Stocks (24/7 Wall St.)
07:21AM	Here's How Tempus AI Is Tapping the Imagining Space (Zacks)
Feb-22-26 08:30AM	Consumer Tech News (Feb 16-20): Big Techs To Boost AI in India, EV Policy Shifts & More (Benzinga)
Feb-20-26 10:55AM	Hims & Hers Accelerates AI Preventive Care and Platform Strategy (Zacks)
09:04AM	AI-Driven Innovation Accelerates Tempus AI's Expansion Across MedTech (Zacks)
Feb-19-26 03:19PM	2 Tech Bets Cathie Wood is Quietly Trimming Right Now: Should You Too? (Barchart) +6.77%
02:01PM	Tempus Shares Jump On AI Cancer Tool (GuruFocus.com)
12:04PM	Tempus AI Stock Jumps As Mizuho Starts Coverage, Earnings Scheduled For Next Week (Benzinga)
09:40AM	Loading…
09:40AM	Shopify, eBay upgraded: Wall Street's top analyst calls (The Fly)
09:15AM	Unlocking Q4 Potential of Tempus (TEM): Exploring Wall Street Estimates for Key Metrics (Zacks)
08:09AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Analog Devices, Chewy, Credo Technology, eBay, Fiverr, Shopify, Verizon, and More (24/7 Wall St.)
Feb-18-26 11:52AM	Why Tempus AI Stock Is Up Today And What to Watch Before Next Weeks Earnings (24/7 Wall St.) +6.85%
11:12AM	What's Going On With Tempus AI Stock Today? (Benzinga)
09:41AM	Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy? (Zacks)
08:30AM	Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm (Business Wire)
Feb-17-26 04:44PM	Cathie Wood Adds 210K Shares to a Rising AI Bet With Upside of 102% (Barchart)
11:32AM	Market Movers: Citi Bullish on NVDA Heading into Earnings (24/7 Wall St.)
11:20AM	Tempus AI & Median Partner to Add AI Lung Cancer Screening to Pixel (Zacks)
09:43AM	Dollar General downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
07:49AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Albemarle, BitGo Holdings, Chevron, Dollar General, Equifax, Shopify, Southwest Airlines, Visa, and More (24/7 Wall St.)
Feb-13-26 09:33AM	Should You Buy, Hold or Sell Tempus AI Stock Pre-Q4 Earnings Release? (Zacks)
Feb-12-26 09:22PM	Cathie Wood's Ark Scoops Up $12.4 Million In Beaten-Down Robinhood - Dumps More Airbnb Shares (Benzinga) -5.28%
04:05PM	Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform (Business Wire)
04:05PM	Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis LCS Software as a Medical Device in the United States (Business Wire)
Feb-11-26 11:13AM	HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell? (Zacks)
Feb-10-26 09:54AM	Jim Cramer on Tempus (TEM): "It's Going to Go Back Down Again" (Insider Monkey)
08:30AM	Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24 (Business Wire)
Feb-04-26 10:17PM	Tempus AI, Inc. (TEM): A Bull Case Theory (Insider Monkey)
07:00AM	Ambry's Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes (Business Wire)
Feb-02-26 07:00AM	Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield (Business Wire)
Feb-01-26 06:50PM	Here Are Congresswoman Nancy Pelosi's Initial Stock Moves in 2026: They Include Nvidia, Alphabet, and Amazon Stocks, and Others (Motley Fool)
08:30AM	Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones (Insider Monkey)
Jan-29-26 09:25AM	AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift (PR Newswire)
08:47AM	TEM vs. DOCS: Which Medical-Tech Stock Looks Promising Amid AI Boom? (Zacks)
Jan-27-26 11:09AM	Nancy Pelosi Just Doubled Down on AI Again (24/7 Wall St.)
08:30AM	Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers (Business Wire)
Jan-26-26 08:56PM	Cathie Wood Bets Big On AI Trifecta: Ark Deploys $1.4 Million Across Medical, Autonomous Driving Sectors (Benzinga)
06:18PM	Pelosi's Bullish 2026 Buy List: AI, Power & Dividends (MarketBeat)
02:21PM	Nancy Pelosi Discloses New Stock Trades: Here's What She's Loading Up On - And What's She's Selling (Benzinga)
01:26PM	Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday? (Benzinga)
10:20AM	Hims & Hers Scales Platform-Led Digital Healthcare Access and Care (Zacks)
09:40AM	How TEM Is Capitalizing on AI-Driven Pathology Market Growth (Zacks)
Jan-22-26 09:06PM	Cathie Wood Loads Up On This Robotaxi Stock, Ark Dumps Roku In Latest Trades (Benzinga)
12:42PM	HIMS vs. TEM: Which Health-Tech Stock Looks More Compelling? (Zacks)
10:10AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Jan-21-26 09:06PM	Cathie Wood Doubles Down On Netflix Despite Weak Guidance, Ark Invest Dumps This Social Media Stock (Benzinga)
04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
08:30AM	Tempus Announces the Launch of Paige Predict (Business Wire)
07:57AM	Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention (Zacks)
Jan-20-26 12:05AM	Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? (Benzinga) -5.05%
Jan-13-26 07:48AM	Tempus AI (TEM) Soars 15% on $1.1-Billion Deal (Insider Monkey)
07:30AM	TEM's Collab for Oncology Patient Population Is Gaining Attention (Zacks)
Jan-12-26 07:27PM	Why Tempus AI Stock Rose Today (Motley Fool)
04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily)
02:53PM	Why Tempus AI Stock Is Trading Higher On Monday? (Benzinga)
01:35PM	Why Tempus AI Stock Jumped on Monday? (GuruFocus.com)
01:08PM	Tempus AI's Pharma Momentum Accelerates (GuruFocus.com)
12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga)
10:58AM	Nancy Pelosi's Latest Trades Are Heating Up - Tempus AI's 100% Stock Surge Is Leading The Charge (Benzinga)
10:56AM	JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop (Investor's Business Daily)
08:30AM	Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology (Business Wire)
07:51AM	Tempus AI Stock Rallies 105% in a Year: Should Investors Still Hold? (Zacks)
07:00AM	Northwestern Medicine Selects Tempus to Expand Genomic Testing (Business Wire)
05:47AM	Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth (Benzinga)
05:33AM	Stock Market Today: Dow Jones, S&P 500 Futures Tumble As DOJ Serves Federal Reserve-Vistra, Tempus AI, Alibaba In Focus (Benzinga)
Jan-11-26 05:30PM	Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion (Business Wire)
05:00PM	Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results (Business Wire)
Jan-09-26 07:45AM	Tempus AI Stock Surges 82.4% in a Year: What's Driving It? (Zacks)
Jan-08-26 06:18PM	Inverse Cramer Wins Again: Opposite Picks Of Investor Beat Nancy Pelosi In 2025 (Benzinga)
08:30AM	Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO Gastrointestinal Cancers Symposium (Business Wire)
Jan-07-26 07:33AM	TEM's Stable Solvency and Financial Strength Are Gaining Attention (Zacks)
Jan-06-26 08:30AM	Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +7.48%
Jan-05-26 12:43PM	Hims & Hers Expands Data-Driven, AI-Enabled Care and Personalization (Zacks)
Jan-02-26 09:10AM	TD Cowen Reaffirms Hold Rating on Tempus AI (TEM), Cites the Company's Position to be a Leader (Insider Monkey) +5.61%
Dec-30-25 11:47PM	Canaccord Lowers Price Objective On Tempus AI, Inc. (TEM) (Insider Monkey)
07:32AM	How Tempus AI Is Building Scale While Near-Term Risks Persist (Zacks)
Dec-29-25 08:48AM	TEM vs. HIMS: Which Medical Info Systems Stock Offers Greater Upside (Zacks)
Dec-26-25 07:18AM	How Tempus AI Is Advancing Toward Regulatory Pricing Catch-Up (Zacks)

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Epstein David R	Director	Mar 02 '26	Sale	50.69	250	12,672	25,801	Mar 04 04:30 PM
Rogers James William	Chief Financial Officer	Mar 02 '26	Sale	50.69	11,414	578,576	127,248	Mar 04 04:30 PM
JAMES ROGERS	Officer	Mar 02 '26	Proposed Sale	53.25	13,583	723,295		Mar 02 04:40 PM
DAVID R. EPSTEIN	Director	Mar 02 '26	Proposed Sale	53.25	870	46,328		Mar 02 04:38 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 19 '26	Sale	58.87	166,250	9,787,605	8,908,283	Feb 20 09:45 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 19 '26	Sale	59.05	13,587	802,312	1,989,626	Feb 20 09:45 PM
Phelps Erik	EVP, Chief Admin. Officer	Feb 19 '26	Sale	59.43	9,464	562,472	79,816	Feb 20 06:45 PM
Bartolucci Ryan M	Chief Accounting Officer	Feb 19 '26	Sale	59.05	2,902	171,363	41,159	Feb 20 06:45 PM
Polovin Andrew	EVP, Chief Legal Officer	Feb 20 '26	Sale	60.31	10,949	660,292	126,918	Feb 20 06:45 PM
Polovin Andrew	EVP, Chief Legal Officer	Feb 19 '26	Sale	59.05	8,143	480,844	99,447	Feb 20 06:45 PM
Fukushima Ryan	Chief Executive Officer, Data	Feb 19 '26	Sale	59.05	9,592	566,408	694,354	Feb 20 06:45 PM
Rogers James William	Chief Financial Officer	Feb 19 '26	Sale	59.05	10,084	595,460	101,166	Feb 20 06:45 PM
ERIK PHELPS	Officer	Feb 20 '26	Proposed Sale	59.96	3,823	229,227		Feb 20 04:28 PM
ANDREW POLOVIN	Officer	Feb 20 '26	Proposed Sale	59.96	10,949	656,502		Feb 20 04:25 PM
Ryan M. Bartolucci	Officer	Feb 19 '26	Proposed Sale	56.16	2,902	162,976		Feb 19 09:24 PM
Andrew Polovin	Officer	Feb 19 '26	Proposed Sale	56.16	8,143	457,311		Feb 19 09:22 PM
Eric Paul Lefkofsky	Officer	Feb 19 '26	Proposed Sale	56.16	13,587	763,046		Feb 19 09:20 PM
Ryan Fukushima	Officer	Feb 19 '26	Proposed Sale	56.16	9,592	538,687		Feb 19 09:17 PM
Erik Phelps	Officer	Feb 19 '26	Proposed Sale	56.16	5,650	317,304		Feb 19 09:15 PM
James William Rogers	Officer	Feb 19 '26	Proposed Sale	56.16	10,084	566,317		Feb 19 09:13 PM
ERIK PHELPS	Officer	Feb 19 '26	Proposed Sale	56.16	3,814	214,194		Feb 19 04:43 PM
Eric Lefkofsky	Officer	Feb 19 '26	Proposed Sale	56.16	166,250	9,336,600		Feb 19 04:08 PM
Tempus AI, Inc.	10% Owner	Nov 18 '25	Buy	7.67	64,750	496,632	12,783,550	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 25 '25	Buy	10.62	23,600	250,665	12,918,346	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 22 '25	Buy	8.93	28,000	250,040	13,039,067	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 21 '25	Buy	9.40	26,499	249,190	12,869,521	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 24 '25	Buy	9.87	25,225	248,971	12,894,746	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 19 '25	Buy	8.12	30,645	248,837	12,814,195	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Nov 20 '25	Buy	8.63	28,827	248,777	12,843,022	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 17 '25	Buy	7.86	31,650	248,769	12,949,996	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 19 '25	Buy	8.39	29,641	248,688	13,011,067	Feb 13 05:24 PM
Tempus AI, Inc.	10% Owner	Dec 18 '25	Buy	7.91	31,430	248,611	12,981,426	Feb 13 05:24 PM
Epstein David R	Director	Feb 02 '26	Sale	59.41	370	21,982	26,051	Feb 04 04:30 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jan 28 '26	Sale	65.56	166,250	10,899,207	8,941,533	Jan 30 04:15 PM
Eric Lefkofsky	Officer	Jan 28 '26	Proposed Sale	66.81	166,250	11,107,162		Jan 28 04:21 PM
Fukushima Ryan	Chief Operating Officer	Jan 05 '26	Sale	64.26	5,000	321,300	148,808	Jan 07 06:25 PM
Doudna Jennifer A	Director	Jan 02 '26	Sale	60.17	1,250	75,212	22,702	Jan 06 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Dec 18 '25	Sale	63.99	166,250	10,638,478	8,974,783	Dec 22 05:41 PM
Eric Lefkofsky	Officer	Dec 18 '25	Proposed Sale	64.61	166,250	10,741,413		Dec 18 04:39 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Dec 16 '25	Sale	67.42	1,302	87,781	89,280	Dec 18 04:15 PM
ERIK PHELPS	Officer	Dec 16 '25	Proposed Sale	68.67	1,302	89,408		Dec 16 04:29 PM
Rogers James William	Chief Financial Officer	Dec 11 '25	Sale	73.20	19,966	1,461,479	111,250	Dec 12 04:30 PM
JAMES ROGERS	Officer	Dec 11 '25	Proposed Sale	75.07	19,966	1,498,848		Dec 11 04:23 PM
Frederick Wayne A.I.	Director	Dec 05 '25	Sale	77.23	3,675	283,820	24,836	Dec 09 04:15 PM
WAYNE FREDERICK	Director	Dec 05 '25	Proposed Sale	77.23	3,675	283,802		Dec 05 04:15 PM
Epstein David R	Director	Dec 01 '25	Sale	75.55	250	18,888	26,421	Dec 03 04:50 PM
Fukushima Ryan	Chief Operating Officer	Dec 01 '25	Sale	75.72	5,000	378,620	153,808	Dec 03 04:50 PM
Doudna Jennifer A	Director	Dec 01 '25	Sale	75.55	676	51,072	23,952	Dec 03 04:50 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 24 '25	Sale	74.10	166,250	12,319,125	9,008,033	Nov 25 04:30 PM
Polovin Andrew	EVP and General Counsel	Nov 24 '25	Sale	75.00	12,874	965,550	107,590	Nov 25 04:30 PM
Eric Lefkofsky	Officer	Nov 20 '25	Proposed Sale	70.40	166,250	11,703,285		Nov 24 06:11 PM
ANDREW POLOVIN	Officer	Nov 24 '25	Proposed Sale	70.29	12,874	904,913		Nov 24 04:29 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 20 '25	Sale	68.97	166,250	11,466,099	9,041,283	Nov 20 07:56 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 18 '25	Sale	65.54	16,829	1,102,944	2,003,213	Nov 20 07:56 PM
Rogers James William	Chief Financial Officer	Nov 18 '25	Sale	65.54	7,257	475,611	131,216	Nov 20 07:05 PM
Polovin Andrew	EVP and General Counsel	Nov 19 '25	Sale	68.06	6,387	434,707	120,464	Nov 20 07:05 PM
Polovin Andrew	EVP and General Counsel	Nov 18 '25	Sale	65.54	5,205	341,126	126,851	Nov 20 07:05 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Nov 18 '25	Sale	65.54	3,533	231,547	90,582	Nov 20 07:05 PM
Fukushima Ryan	Chief Operating Officer	Nov 18 '25	Sale	65.54	10,099	661,870	829,081	Nov 20 07:05 PM
Bartolucci Ryan M	Chief Accounting Officer	Nov 18 '25	Sale	65.54	1,834	120,197	44,061	Nov 20 07:05 PM
Eric Lefkofsky	Officer	Nov 20 '25	Proposed Sale	69.09	166,250	11,486,212		Nov 20 04:46 PM
ANDREW POLOVIN	Officer	Nov 19 '25	Proposed Sale	66.77	6,387	426,460		Nov 19 04:22 PM
Ryan M. Bartolucci	Officer	Nov 18 '25	Proposed Sale	66.39	1,834	121,759		Nov 18 07:09 PM
Ryan Fukushima	Officer	Nov 18 '25	Proposed Sale	66.39	10,099	670,473		Nov 18 07:08 PM
Eric Paul Lefkofsky	Officer	Nov 18 '25	Proposed Sale	66.39	16,829	1,117,277		Nov 18 07:07 PM
Andrew Polovin	Officer	Nov 18 '25	Proposed Sale	66.39	5,205	345,560		Nov 18 07:05 PM
James William Rogers	Officer	Nov 18 '25	Proposed Sale	66.39	7,257	481,792		Nov 18 07:04 PM
Erik Phelps	Officer	Nov 18 '25	Proposed Sale	66.39	3,533	234,556		Nov 18 07:03 PM
Doudna Jennifer A	Director	Nov 11 '25	Sale	71.45	1,926	137,613	24,628	Nov 13 04:15 PM
JENNIFER DOUDNA	Director	Nov 11 '25	Proposed Sale	71.78	3,852	276,497		Nov 12 07:03 AM
Fukushima Ryan	Chief Operating Officer	Nov 03 '25	Sale	89.03	5,000	445,160	125,000	Nov 05 04:15 PM
Epstein David R	Director	Nov 03 '25	Sale	90.00	370	33,300	26,671	Nov 05 04:15 PM
VANESSA L KUBO	Officer	Nov 03 '25	Proposed Sale	89.85	20,000	1,797,000		Nov 03 04:26 PM
DAVID R. EPSTEIN	Director	Nov 03 '25	Proposed Sale	89.85	990	88,952		Nov 03 04:25 PM
LEFKOFSKY ERIC P	CEO and Chairman	Oct 28 '25	Sale	89.11	332,500	29,629,006	9,074,532	Oct 30 04:31 PM
Eric Lefkofsky	Officer	Oct 28 '25	Proposed Sale	91.58	332,500	30,450,350		Oct 28 04:09 PM
Fukushima Ryan	Chief Operating Officer	Oct 06 '25	Sale	92.32	5,000	461,606	130,000	Oct 08 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Sep 25 '25	Sale	76.56	332,500	25,457,014	9,141,032	Sep 29 04:33 PM
Eric Lefkofsky	Officer	Sep 25 '25	Proposed Sale	84.13	332,500	27,973,225		Sep 25 07:04 PM
Fukushima Ryan	Chief Operating Officer	Sep 02 '25	Sale	75.80	10,000	758,028	135,000	Sep 04 04:15 PM
Epstein David R	Director	Sep 02 '25	Sale	73.64	250	18,410	27,041	Sep 04 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 27 '25	Sale	74.10	332,500	24,637,581	9,207,533	Aug 29 05:13 PM
Leonsis Theodore	Director	Aug 26 '25	Sale	75.83	20,000	1,516,600	66,756	Aug 28 04:15 PM
Eric Lefkofsky	Officer	Aug 27 '25	Proposed Sale	75.90	332,500	25,236,750		Aug 27 04:19 PM
Leonsis Theodore	Director	Aug 26 '25	Proposed Sale	75.83	20,000	1,516,650		Aug 26 01:27 PM
Polovin Andrew	EVP and General Counsel	Aug 19 '25	Sale	74.65	5,398	402,982	132,056	Aug 21 04:15 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Aug 19 '25	Sale	74.65	3,664	273,532	94,115	Aug 21 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 19 '25	Sale	74.65	17,458	1,303,307	2,020,042	Aug 21 04:15 PM
Fukushima Ryan	Chief Operating Officer	Aug 19 '25	Sale	74.65	17,460	1,303,456	839,180	Aug 21 04:15 PM
Rogers James William	Chief Financial Officer	Aug 19 '25	Sale	74.65	7,528	561,994	138,473	Aug 21 04:15 PM
Bartolucci Ryan M	Chief Accounting Officer	Aug 19 '25	Sale	74.65	1,904	142,141	45,895	Aug 21 04:15 PM
Erik Phelps	Officer	Aug 19 '25	Proposed Sale	78.45	3,664	287,441		Aug 20 07:19 AM
Andrew Polovin	Officer	Aug 19 '25	Proposed Sale	78.45	5,398	423,473		Aug 20 07:17 AM
Ryan Fukushima	Officer	Aug 19 '25	Proposed Sale	78.45	17,460	1,369,737		Aug 20 07:15 AM
Eric Paul Lefkofsky	Officer	Aug 19 '25	Proposed Sale	78.45	17,458	1,369,580		Aug 20 07:14 AM
James William Rogers	Officer	Aug 19 '25	Proposed Sale	78.45	7,528	590,572		Aug 19 09:59 PM
Ryan M. Bartolucci	Officer	Aug 19 '25	Proposed Sale	78.45	1,904	149,369		Aug 19 09:56 PM
Leonsis Theodore	Director	Aug 13 '25	Proposed Sale	69.90	44,000	3,075,786		Aug 18 02:44 PM
Leonsis Theodore	Director	Aug 13 '25	Sale	69.90	44,000	3,075,600	86,756	Aug 15 09:21 PM
Epstein David R	Director	Aug 01 '25	Sale	55.16	370	20,409	27,291	Aug 05 04:15 PM

Open in Screener

PFE

Pfizer Inc

Mar 10 • 04:00PM ET

27.16

+0.35 1.31 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: BMY MRK SNY AMGN ABBV NVS JNJ GSK LLY AZN-D

| Held by: VTI VOO IVV SPY VTV XLV VYM VHT DVY FDL

Index	S&P 500	P/E	20.04	EPS (ttm)	1.36	Insider Own	0.10%	Shs Outstand	5.69B	Perf Week	2.18%
Market Cap	154.44B	Forward P/E	9.60	EPS next Y	2.83	Insider Trans	0.00%	Shs Float	5.68B	Perf Month	-0.22%
Enterprise Value	208.56B	PEG	-	EPS next Q	0.73	Inst Own	67.06%	Short Float	2.58%	Perf Quarter	4.34%
Income	7.75B	P/S	2.47	EPS this Y	-8.14%	Inst Trans	0.28%	Short Ratio	3.08	Perf Half Y	10.63%
Sales	62.58B	P/B	1.79	EPS next Y	-4.39%	ROA	3.67%	Short Interest	146.38M	Perf YTD	9.08%
Book/sh	15.21	P/C	11.36	EPS next 5Y	-9.06%	ROE	8.87%	52W High	27.94 -2.79%	Perf Year	1.95%
Cash/sh	2.39	P/FCF	17.02	EPS past 3/5Y	-37.19% -3.57%	ROIC	5.15%	52W Low	20.92 29.86%	Perf 3Y	-31.05%
Dividend Est.	1.75 (6.45%)	EV/EBITDA	8.65	Sales past 3/5Y	-14.56% 8.48%	Gross Margin	66.23%	Volatility	2.56% 2.10%	Perf 5Y	-22.24%
Dividend TTM	1.72 (6.33%)	EV/Sales	3.33	EPS Y/Y TTM	-3.74%	Oper. Margin	27.99%	ATR (14)	0.62	Perf 10Y	-3.15%
Dividend Ex-Date	Jan 23, 2026	Quick Ratio	0.87	Sales Y/Y TTM	-1.65%	Profit Margin	12.38%	RSI (14)	54.36	Recom	2.59
Dividend Gr. 3/5Y	2.23% 2.37%	Current Ratio	1.16	EPS Q/Q	-509.90%	SMA20	0.08%	Beta	0.42	Target Price	28.35
Payout	126.85%	Debt/Eq	0.78	Sales Q/Q	-1.16%	SMA50	3.19%	Rel Volume	0.90	Prev Close	26.81
Employees	75000	LT Debt/Eq	0.74	Earnings	Feb 03 BMO	SMA200	7.99%	Avg Volume	47.49M	Price	27.16
IPO	Jan 17, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.42% 4.20%	Trades		Volume	42,765,640	Change	1.31%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-02-26	Upgrade	Argus	Hold → Buy	$35
Feb-25-26	Initiated	RBC Capital Mkts	Underperform	$25
Feb-20-26	Initiated	Barclays	Underweight	$25
Feb-12-26	Downgrade	Daiwa Securities	Outperform → Neutral	$27
Jan-07-26	Resumed	UBS	Neutral	$25
Dec-02-25	Resumed	Citigroup	Neutral	$26
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$30
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$24
Dec-10-24	Resumed	BofA Securities	Neutral	$29
Nov-15-24	Initiated	Wolfe Research	Underperform	$25
Oct-25-24	Resumed	Citigroup	Neutral	$30
Oct-17-24	Initiated	Bernstein	Mkt Perform	$32
Aug-07-24	Upgrade	Daiwa Securities	Neutral → Outperform
Mar-22-24	Downgrade	Argus	Buy → Hold
Feb-23-24	Initiated	Guggenheim	Buy	$36
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$32
Oct-20-23	Resumed	UBS	Neutral	$36 → $34
Oct-16-23	Upgrade	Jefferies	Hold → Buy	$38 → $39
Jul-17-23	Reiterated	JP Morgan	Neutral	$45 → $41
Jul-14-23	Initiated	HSBC Securities	Buy	$50

Show Previous Ratings

Mar-10-26 03:00PM	BioNTech SE (BNTX) Q4 2025 Earnings Call Highlights: Strategic Advances Amidst Revenue Challenges (GuruFocus.com)
02:49PM	BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz (Benzinga)
02:38PM	Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer's Patent Shake-Up (Investor's Business Daily)
09:24AM	BioNTech Reports Earnings. That's Not Why the Stock Is Down 17%. (Barrons.com)
08:40AM	BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture (Benzinga)
08:19AM	Loading…
08:19AM	BioNTechs Founding Duo Will Leave to Start New mRNA Firm (Bloomberg)
07:18AM	BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. (Barrons.com)
07:00AM	Xenon hits a home run in epilepsy; FDA restarts review of Duchenne cell therapy (BioPharma Dive)
Mar-09-26 02:14PM	Roches oral SERD fails in Phase III breast cancer trial (Clinical Trials Arena)
01:42PM	Factbox-Global drugmakers rush to boost US presence as tariff threat looms (Reuters)
12:22PM	Why Is Olema Pharmaceuticals Stock Dropping On Monday? (Benzinga)
10:21AM	Roche Shares Drop Up to 7.5% After Breast Cancer Pill Misses Trial Goal (GuruFocus.com)
08:19AM	Roches prized breast cancer pill fails closely watched study (BioPharma Dive)
07:42AM	Stocks to Watch Monday: Moderna, Live Nation, Pfizer, Hims & Hers (The Wall Street Journal)
06:45AM	Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis (Business Wire)
05:44AM	Loading…
05:44AM	Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study (The Wall Street Journal)
05:43AM	Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer, Hims & Hers (The Wall Street Journal)
Mar-08-26 04:49PM	These 8 drugs could help fight dementia - and they're already on the market (MarketWatch)
Mar-07-26 12:26PM	C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference (MarketBeat)
Mar-06-26 11:30AM	AbbVie (ABBV) Up 6.1% Since Last Earnings Report: Can It Continue? (Zacks)
09:00AM	Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:14AM	China Clears Weight-Loss Shot As Pfizer Enters Crowded Market (Benzinga)
05:13AM	Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs (BioPharma Dive)
03:53AM	BridgeBio Pharma Talks Atrubie Momentum, Phase 3 Wins as Tafamidis IP Trial Looms (MarketBeat)
Mar-05-26 11:30AM	Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound? (Zacks)
08:45AM	Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations? (Zacks)
Mar-04-26 08:54PM	Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline (Insider Monkey)
10:36AM	Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference (MarketBeat)
08:55AM	NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals (PR Newswire)
12:48AM	Pfizer Inc. (PFE) and Astellas Report Positive Phase 3 EV-304 Results for PADCEV Plus Keytruda in Bladder Cancer (Insider Monkey)
07:24PM	Loading…
Mar-03-26 07:24PM	Analyst Report: ICU Medical, Inc. (Morningstar Research)
03:35PM	The Dividend Safe Harbor: 2 Stocks to Watch (MarketBeat)
09:10AM	Immunology, Neuroscience Step Up as Key Growth Engines for J&J (Zacks)
Mar-02-26 12:42PM	BMY Gains 11.4% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
11:00AM	Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026? (Zacks)
09:53AM	Netflix upgraded, Pinterest downgraded: Wall Street's top analyst calls (The Fly)
Mar-01-26 04:27AM	Pfizer Inc. (PFE) and Astellas Pharma Announce Positive Results From the Phase 3 EV-304 Clinical Trial for PADCEVTM (Insider Monkey)
Feb-27-26 10:30AM	The Zacks Analyst Blog Highlights Meta Platforms, Netflix, Pfizer, SIFCO Industries and Altigen Communications (Zacks)
10:24AM	Amneal Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
10:00AM	PADCEV + Keytruda Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer (Business Wire)
08:26AM	Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates (Zacks)
07:01AM	Pfizer (PFE) Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC (Insider Monkey)
12:07AM	Novavax Q4 Earnings Call Highlights (MarketBeat)
Feb-26-26 07:30PM	Love Dividends? 1 Stock to Buy Now With a Yield Over 6%. (Barchart)
04:11PM	Novavax Inc (NVAX) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... (GuruFocus.com)
04:11PM	Top Research Reports for Meta, Netflix & Pfizer (Zacks)
02:24PM	Analyst Report: Viatris Inc. (Morningstar Research)
10:59AM	Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference (MarketBeat)
08:46AM	Novavax shares subdued despite earnings, revenue beat (Investing.com)
08:30AM	Novavax, Inc. Q4 2025 Earnings Call Summary (Moby)
04:32AM	Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC (MarketBeat)
Feb-25-26 09:50PM	RBC Capital Initiates Pfizer (PFE) with $25 Target, Warns of Structural Revenue Headwinds (Insider Monkey)
01:22PM	Pfizer's Braftovi Regimen Wins Complete FDA Nod For Colorectal Cancer Treatment (Benzinga)
01:20PM	Analyst Report: Haleon plc (Morningstar Research)
11:33AM	Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment (Benzinga)
09:57AM	Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie (Investing.com)
08:49AM	Can J&J Sustain Its Double-Digit Oncology Growth Streak? (Zacks)
08:26AM	Pfizer Stock: Is PFE Underperforming the Healthcare Sector? (Barchart)
Feb-24-26 04:29PM	'Stablecoin Summer': Stripe Makes Tender Offer at $159 Billion Valuation (decrypt)
02:45PM	Pfizer Secures $495 Million China Obesity Drug Deal (GuruFocus.com)
02:29PM	U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer (Business Wire)
10:44AM	Arvinas Q4 Earnings Call Highlights (MarketBeat)
09:35AM	Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity (PR Newswire)
08:27AM	What's Going On With Kyntra Bio Stock Tuesday? (Benzinga)
06:00AM	Novo to cut GLP-1 drug prices; Palvella soars on study data (BioPharma Dive)
Feb-23-26 10:45AM	Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings? (Zacks)
10:00AM	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Business Wire)
09:00AM	Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:00AM	Telescope Innovations Installs Second Self-Driving Lab at Pfizer (TMX Newsfile)
Feb-20-26 11:02AM	Moderna Faces Lawsuit From BioNTech Over Next-Generation COVID-19 Shot (Benzinga)
10:46AM	AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026? (Zacks)
08:08AM	Barclays launches U.S. biopharma coverage with four preferred picks (Investing.com)
03:58AM	Analyst Report: ICU Medical, Inc. (Morningstar Research)
03:34AM	Pfizer Inc (PFE) Announces Positive Results from BREAKWATER Trial (Insider Monkey)
Feb-19-26 10:15AM	Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure (Zacks)
09:53AM	Where is Pfizer Inc. (PFE) Headed? (Insider Monkey)
Feb-18-26 11:20AM	Moderna stock surges as FDA reverses course, agrees to review new flu shot (Yahoo Finance)
03:20AM	Analyst Report: Pfizer Inc. (Morningstar Research)
Feb-17-26 11:04AM	Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk (Investor's Business Daily)
10:30AM	CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock? (Zacks)
10:15AM	Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial (Benzinga)
06:45AM	Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer (Business Wire)
Feb-14-26 02:04PM	Oric Pharmaceuticals Highlights 2025 Milestones at Guggenheim, Targets Phase 3 Prostate Trial in 1H25 (MarketBeat)
01:28AM	Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings (Insider Monkey)
Feb-13-26 08:57PM	Analyst Report: ICU Medical, Inc. (Morningstar Research)
04:57PM	Analyst Report: Zoetis Inc. (Morningstar Research)
09:57AM	Is Pfizer Inc. (PFE) One of the Best Medical Research Stocks to Buy According to Hedge Funds? (Insider Monkey)
Feb-12-26 12:00PM	Kahn Brothers Reduces Stake in Pfizer Inc by 21.66% (GuruFocus.com)
10:38AM	MDGL Strengthens MASH Franchise With New Genetic Approaches (Zacks)
08:00AM	Here Are Thursdays Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More (24/7 Wall St.)
Feb-11-26 01:30PM	Pfizer Reports Strong Earnings Outlook - Unusual Call Options Activity Shows Investors are Bullish (Barchart)
12:57PM	Pharma companies left out of Trump's drug-pricing deals look for way in (Reuters)
10:35AM	Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders (Insider Monkey)
08:09AM	Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff? (Zacks)
08:01AM	CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside (Zacks)
Feb-10-26 04:51PM	Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. (Barrons.com)
11:06AM	Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line? (Zacks)
09:00AM	Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
06:41AM	Pfizer Inc. (PFE) Announces FDA's Grant of Priority Review for HYMPAVZI (marstacimab) sBLA (Insider Monkey)
12:37AM	5 Revealing Analyst Questions From Pfizer's Q4 Earnings Call (StockStory)

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SAHNI PAYAL	Executive Vice President	Feb 25 '26	Option Exercise	33.82	56,888	1,923,952	82,816	Feb 27 06:35 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 25 '26	Option Exercise	33.82	122,907	4,156,715	282,186	Feb 27 06:35 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 25 '26	Option Exercise	33.82	17,558	593,812	29,744	Feb 27 06:35 PM
BOURLA ALBERT	Chairman & CEO	Feb 25 '26	Option Exercise	33.82	491,626	16,626,791	864,215	Feb 27 06:34 PM
Fonseca Lidia	Executive Vice President	Feb 25 '26	Option Exercise	33.82	56,888	1,923,952	101,579	Feb 27 06:34 PM
McDermott Michael	Executive Vice President	Feb 25 '26	Option Exercise	33.82	37,925	1,282,624	114,534	Feb 27 06:34 PM
Dolsten Mikael	Former Officer	May 23 '25	Proposed Sale	23.09	59,781	1,380,632		May 23 10:54 AM
Dolsten Mikael	Former Officer	May 05 '25	Proposed Sale	23.87	55,000	1,312,736		May 05 04:45 PM

TEM

Tempus AI Inc

PFE

Pfizer Inc

Upgrade your FINVIZ experience